Inhibikase Therapeutics, Inc. (NASDAQ:IKT) Receives Consensus Rating of "Buy" from Analysts
Inhibikase Therapeutics, Inc. (NASDAQ:IKT - Get Free Report) has been given a consensus recommendation of "Buy" by the five research firms that are currently covering the stock, Marketbeat Ratings...